Peter J. Lenting

14.2k total citations · 1 hit paper
208 papers, 10.0k citations indexed

About

Peter J. Lenting is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Peter J. Lenting has authored 208 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 173 papers in Hematology, 55 papers in Immunology and 41 papers in Genetics. Recurrent topics in Peter J. Lenting's work include Platelet Disorders and Treatments (124 papers), Blood Coagulation and Thrombosis Mechanisms (70 papers) and Hemophilia Treatment and Research (64 papers). Peter J. Lenting is often cited by papers focused on Platelet Disorders and Treatments (124 papers), Blood Coagulation and Thrombosis Mechanisms (70 papers) and Hemophilia Treatment and Research (64 papers). Peter J. Lenting collaborates with scholars based in France, Netherlands and United States. Peter J. Lenting's co-authors include Cécile V. Denis, Olivier D. Christophe, Koen Mertens, Jan A. van Mourik, Philip G. de Groot, Caterina Casari, Charlotte Kawecki, Evelyn Groot, Ronan Pendu and Abhay P. Sagare and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Peter J. Lenting

202 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms

2004 697 citations Peter J. Lenting et al. profile →

Peers

Countries citing papers authored by Peter J. Lenting

Since Specialization

Citations

This map shows the geographic impact of Peter J. Lenting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Lenting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Lenting more than expected).

Fields of papers citing papers by Peter J. Lenting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Lenting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Lenting. The network helps show where Peter J. Lenting may publish in the future.

Co-authorship network of co-authors of Peter J. Lenting

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Lenting. A scholar is included among the top collaborators of Peter J. Lenting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Lenting. Peter J. Lenting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	<i>Erratum</i> to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice” 2025 ·Haematologica ·(unknown), (unknown), Marie‐Annick Clavel, (unknown), Ivan Peyron, Tovo David, Camille Brochier, François Saller, (unknown), Cécile V. Denis, Olivier D. Christophe, Peter J. Lenting, Vincent Muczynski, Caterina Casari	0
2	Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice 2025 ·Haematologica ·(unknown), (unknown), Marie‐Annick Clavel, (unknown), Ivan Peyron, Tovo David, Camille Brochier, François Saller, (unknown), Cécile V. Denis, Olivier D. Christophe, Peter J. Lenting, Vincent Muczynski, Caterina Casari	2
3	Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody 2025 ·Blood ·Vincent Muczynski, Olivier D. Christophe, (unknown), (unknown), Alain P. Guérin, Caterina Casari, Jenny McIntosh, (unknown), (unknown), Satyen H. Gohil, Peter J. Lenting, Edward G. D. Tuddenham, Amit Nathwani	0
4	A bispecific nanobody for the treatment of von Willebrand disease type 1 2025 ·Blood ·Ivan Peyron, Caterina Casari, (unknown), (unknown), (unknown), (unknown), (unknown), Stéphanie Roullet, Sophie Susen, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis	1
5	PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space 2024 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Erik Sjögren, (unknown), Peter J. Lenting, Marjon H. Cnossen, Ron A. A. Mathôt	1
6	Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy 2023 ·Journal of Thrombosis and Haemostasis ·(unknown), (unknown), Sandrine Delignat, (unknown), (unknown), Maxime Lecerf, (unknown), Rémi Noé, Ivan Peyron, Olivier D. Christophe, Peter J. Lenting, Valérie Proulle, Jenny McIntosh, Amit Nathwani, Jordan D. Dimitrov, Cécile V. Denis, Sébastien Lacroix‐Desmazes	5
7	von Willebrand factor: from figurant to main character in the scene of inflammation 2023 ·Journal of Thrombosis and Haemostasis ·Peter J. Lenting, (unknown), Caterina Casari	1
8	Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in Von Willebrand disease murine models 2023 ·Blood ·Stéphanie Roullet, (unknown), Julie Rayes, (unknown), (unknown), Andrew J. Ditto, (unknown), Christa L. Pawlowski, (unknown), Frédéric Adam, Caterina Casari, Olivier D. Christophe, Michael A. Bruckman, Peter J. Lenting, Anirban Sen Gupta, Cécile V. Denis	19
9	Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S 2022 ·Journal of Thrombosis and Haemostasis ·(unknown), Frédéric Adam, (unknown), Elsa P. Bianchini, (unknown), Ivan Peyron, (unknown), Sophie Gandrille, Stella Thomassen, Tilman M. Hackeng, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis, Delphine Borgel, François Saller	2
10	Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization 2022 ·Research and Practice in Thrombosis and Haemostasis ·(unknown), Ivan Peyron, (unknown), Serge Pierre‐Louis, (unknown), Pierre Boisseau, Annika de Jong, Sophie Susen, Jenny Goudemand, Rémi Nevière, (unknown), Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis, Caterina Casari	2
11	A New Class of Tunable Acid-Sensitive Linkers for Native Drug Release Based on the Trityl Protecting Group 2022 ·Bioconjugate Chemistry ·(unknown), Jimmy J. Weterings, (unknown), (unknown), Peter J. Lenting, Cristianne J.F. Rijcken, Tina Vermonden, Wim E. Hennink, Rob M. J. Liskamp	9
12	A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization 2021 ·Lab on a Chip ·(unknown), Gilgueng Hwang, Nassim Arouche, Sina Naserian, Abdelmounaïm Harouri, Valeria Lotito, Caterina Casari, (unknown), (unknown), (unknown), Julien Guihaire, Cécile V. Denis, Peter J. Lenting, Abdul I. Barakat, Georges Uzan, Olaf Mercier, Anne‐Marie Haghiri‐Gosnet	17
13	The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells 2021 ·Cardiovascular Research ·Jérémy Lagrange, (unknown), Jean‐Baptiste Michel, (unknown), (unknown), Vincent Muczynski, Paulette Legendre, François Plénat, Guillaume Gauchotte, (unknown), Olivier D. Christophe, Peter J. Lenting, Patrick Lacolley, Cécile V. Denis, Véronique Regnault	23
14	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor 2021 ·Gene Therapy ·Elena Barbon, Charlotte Kawecki, Solenne Marmier, (unknown), Fanny Collaud, Séverine Charles, Giuseppe Ronzitti, Caterina Casari, Olivier D. Christophe, Cécile V. Denis, Peter J. Lenting, Federico Mingozzi	25
15	von Willebrand disease: what does the future hold? 2021 ·Blood ·Cécile V. Denis, Sophie Susen, Peter J. Lenting	20
16	Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis 2021 ·Blood ·Steven de Maat, (unknown), Arjan D. Barendrecht, Simone M. Smits, (unknown), (unknown), (unknown), (unknown), Michael Szardenings, Nicolas Delaroque, (unknown), Rolf T. Urbanus, Silvie Sebastian, Peter J. Lenting, Christoph E. Hagemeyer, Thomas Renné, Karen Vanhoorelbeke, Claudia Tersteeg, Coen Maas	17
17	Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications 2020 ·Research and Practice in Thrombosis and Haemostasis ·Ivan Peyron, (unknown), (unknown), (unknown), (unknown), Cécile V. Denis, Peter J. Lenting, Caterina Casari, Olivier D. Christophe	10
18	A hemophilia A mouse model for the in vivo assessment of emicizumab function 2020 ·Blood ·(unknown), Ivan Peyron, Olivier D. Christophe, Charlotte Kawecki, Caterina Casari, Vincent Muczynski, Amit Nathwani, Alexandre Kauskot, Peter J. Lenting, Cécile V. Denis	44
19	Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors 2020 ·EMBO Molecular Medicine ·Elena Barbon, (unknown), (unknown), Jean‐François Ottavi, Charlotte Kawecki, Caterina Casari, (unknown), Solenne Marmier, Laetitia van Wittenberghe, Séverine Charles, Fanny Collaud, Cécile V. Denis, Olivier D. Christophe, Federico Mingozzi, Peter J. Lenting	19
20	von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends 2015 ·Blood ·Peter J. Lenting, Olivier D. Christophe, Cécile V. Denis	292

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact